Replies to post #177288 on Biotech Values

[Rocky3]

AbbVie CEO says it won't compete w/ Gilead on price in hep C.

That is consistent with what he has said in the past. And I think a mistake. Good news for GILD. And bad news for payers. No reason to delay treatments, unless you might get the GILD 8 week treatment, if it is priced lower.

Have to wait to see if MRK competes on price in 18-24 months.

Now it is up to GILD. This might encourage a higher price for the all oral ($1500/pill?)

[DewDiligence]

AbbVie CEO says it won't compete w/ Gilead on price in hep C.

Actually, ABBV’s CEO, Rick Gonzalez, didn’t say that ABBV wouldn’t complete with GILD on price. Rather, Gonzalez said that ABBV’s 3-DAA HCV regimen was very well positioned for the marketplace, particularly with respect to cirrhotic and treatment-experienced patients, where ABBV’s data are somewhat more convincing than GILD’s in terms of SVR12 confidence intervals.